Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain

Journal of Immunology

Volumn 172, Issue 1, 2004, Pages 104-113

  Finney, Helene M ^a   Akbar, Arne N ^b   Lawson, Alastair D G ^a  

^a UCB PHARMA   (Belgium)

^b Windeyer Institute of Medical Sciences   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; CD28 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; CELL CLONE; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; ELECTROPORATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0347994955     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.1.104     Document Type: Article

References (81)

1. Gross, G., and Z. Eshhar. 1992. Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J. 6:3370.
2. Eshhar, Z., N. Bach, C. J. Fitzer-Attas, G. Gross, J. Lustgarten, T. Waks, and D. G. Schindler. 1996. The T-body approach: potential for cancer immunotherapy. Springer Semin. Immunopathol. 18:199.
3. Sadelain, M., I. Riviere, and R. Brentjens. 2003. Targeting tumors with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3:35.
4. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:588.
5. Bitton, N., F. Verrier, P. Debre, and G. Gorochov. 1998. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120. Eur. J. Immunol. 28:4177.
6. + T lymphocytes armed with universal T-cell receptors. Blood 84:2878.
7. Brocker, T., and K. Karjalainen. 1995. Signals through T cell receptor-ζ chain alone are insufficient to prime resting T lymphocytes. J. Exp. Med. 181:1653.
8. Brocker, T. 2000. Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96:1999.
9. + T cells in human immunodeficiency virus-infected subjects. Blood 96:785.
10. Walker, R. E., C. M. Bechtel, V. Natarajan, M. Baseler, K. M. Hege, J. A. Metcalf, R. Stevens, A. Hazen, R. M. Blaese, C. C. Chen, et al. 2000. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96:467.
11. Bretcher, P. A., and M. A. Cohn. 1970. A theory of self and non-self discrimination. Science 169:1042.
12. Tan, P., C. Anasetti, J. A. Hansen, J. Melrose, M. Brunvand, J. Bradshaw, J. A. Ledbetter, and P. S. Lindsley. 1993. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand, B7/BB1. J. Exp. Med. 177:165.
13. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, and J. P. Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 6370:607.
14. Liebowitz, D. N., K. P. Lee, and C. H. June. 1998. Costimulatory approaches to adoptive immunotherapy. Curr. Opin. Oncol. 10:533.
15. Alvarez-Vallina, L., and R. E. Hawkins. 1996. Antigen-specific targetting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur. J. Immunol. 26:2304.
16. Krause, A., H.-F. Gou, J.-B. Latouch, C. Tan, N.-K. V. Cheung, and M. A. Sadelain. 1998. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188:619.
17. Finney, H. M., A. D. G. Lawson, C. R. Bebbington, and A. N. C. Weir. 1998. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161:2791.
18. Eshhar, Z., T. Waks, A. Bendavid, and D. G. Schindler. 2001. Functional expression of chimeric receptor genes in human T cells. J. Immunol. Methods 248:67.
19. Hombach, A., A. Wieczarkowiecz, T. Marquardt, C. Heuser, L. Usai, C. Pohl, B. Seliger, and H. Abken. 2001. Tumor-specific T cell activation by recombinant immunoreceptors: CD3ζ signalling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule. J. Immunol. 167:6123.
20. Geiger, T. L., P. Nguyen, D. Leitenberg, and R. A. Flavell. 2001. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 98:2364.
21. Maher, J., R. J. Brentjens, G. Gunset, I. Riviere, and M. Sadelain. 2002. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat. Biotechnol. 20:70.
22. Gilham, D. E., A. O'Neil, C. Hughs, R. D. Guest, N. Kirillova, M. Lehane, and R. E. Hawkins. 2002. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3 ζ-based chimeric immune receptors. J. Immunother. 25:139.
23. Haynes, N. M., J. A. Trapani, M. W. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy. 2002. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J. Immunol. 169:5780.
24. Haynes, N. M., J. A. Trapani, M. W. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy. 2002. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100:3155.
25. Lenschow, D. J., T. S. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
26. Sansom, D. M. 2000. CD28, CTLA-4 and their ligands: who does what and to whom? Immunology 101:169.
27. Alegre, M.-L., K. A. Frauwirth, and C. B. Thompson. 2001. T-cell regulation by CD28 and CTLA-4. Nat. Rev. Immunol. 1:220.
28. June, C. H., J. A. Ledbetter, M. M. Gillespi, T. Lindsten, and C. B. Thompson. 1987. T-cell proliferation involving the CD28 pathway is associated with cyclosporin-resistant interleukin 2 gene expresssion. Mol. Cell. Biol. 12:4472.
29. Jenkins, M. K., P. S. Taylor, S. D. Norton, and K. B. Urdahl. 1991. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J. Immunol. 8:2461.
30. L. Immunity 3:87.
31. Radvanyi, L. G., Y. Shi, and H. Viziri. 1996. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J. Immunol. 156:1788.
32. Lucas, P. J., I. Negishi, K. Nakayama, L. E. Fields, and D. Y. Loh. 1995. Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J. Immunol. 154:5757.
33. Schweitzer, A. N., and A. H. Sharpe. 1998. The complexity of the B7-CD28/CTLA-4 costimulatory pathway. Agents Actions Suppl. 49:33.
34. + T cells. J. Immunol. 164:265.
35. Watts, T. H., and M. A. DeBenedette. 1999. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11:286.
36. Salazar-Fontana, L. I., and B. E. Bierer. 2001. T-lymphocyte coactivator molecules. Curr. Opin. Hematol. 8:5.
37. Sharpe, A. H., and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2:116.
38. Hutloff, A., A. M. Dittrich, K. C. Beier, B. Eljaschewitsch, R. Kraft, I. Anagnostopouls, and R. A. Kroczek. 1999. ICOS is an inducible T-cell costimulator structurally and functionally related to CD28. Nature 397:263.
39. Latza, U., H. Durkop, S. Schnittger, J. Ringeling, F. Eitelbach, M. Hummel, C. Fonatsch, and S. Stein. 1994. The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur. J. Imuunol. 24:677.
40. Alderson, M. R., C. A. Smith., T. W. Tough, T. Davis-Smith, R. J. Armitage, B. Falf, E. Roux, E. Baker, G. R. Sutherland, W. S. Din, and R. G. Goodwin. 1994. Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol. 24:2219.
41. Carreno, B. M., and M. Collins. 2002. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20:29.
42. Beier, K. C., A. Hutloff, A. M. Dittrich, C. Heuck, A. Rauch, K. Büchner, B. Ludewig, H. D. Ochs, H. W. Mages, and R. A. Kroczek. 2000. Induction, binding specificity and function of human ICOS. Eur. J. Immunol. 30:3707.
43. + T cells. J. Immunol. 165:5035.
44. Gonzalo, J. A., J. Tian, T. Delaney, J. Corcoran, J. B. Rottman, J. Lora, A. Al-Garawi, R. Kroczek, J. C. Gutierrez-Ramos, and A. J. Coyle. 2001. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat. Immun. 2:597.
45. Riley, J. L., P. J. Blair, J. T. Musser, R. Abe, K. Tezuka, T. Tsuji, and C. H. June. 2001. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. J. Immunol. 166:4943.
46. McAdam, A. J., R. J. Greenwald, M. A. Levin, T. Chernova, N. Malenkovich, V. Ling, G. J. Freeman, and A. H. Sharpe. 2001. ICOS is critical for CD40-mediated antibody class switching. Nature 409:102.
47. Dong, C., A. E. Juedes, U. A. Teman, S. Shresta, J. P. Allison, N. H. Ruddle, and R. A. Flavell. 2001. ICOS co-stimulatory receptor is essential for T cell activation and function. Nature 409:97.
48. Tafuri, A., A. Shahinian, F. Bladt, S. K. Yoshinaga, M. Jordana, A. Wakeham, L. M. Boucher, D. Bouchard, V. S. F. Cha, G. Duncan, et al. 2001. ICOS is essential for effective T-helper-cell responses. Nature 409:105.
49. Grimbacher, B., A. Hutloff, M. Schlesier, E. Glocker, K. Warnatz, R. Drager, H. Eibel, B. Fischer, A. A. Schaffer, H. Mages, et al. 2003. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat. Immun. 4:261.
50. Flynn, S., K. M. Toeller, C. Raykundalia, M. Goodall, and P. Lane. 1998. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and up-regulates expression of the chemokine receptor, blr-1. J. Exp. Med. 188:297.
51. Gramaglia, I., A. D. Weinberg, M. Lemon, and M. Croft. 1998. OX40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161:6510.
52. + T cells into high IL-4-producing effectors. Blood 92:3338.
53. L and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15:445.
54. Weinberg, A. D., M. M. Rivera, R. Prevell, A. Morris, T. Ramstead, J. T. Vetto, W. J. Urba, G. Alvord, C. Bunce, and J. Shields. 2000. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164:2160.
55. Gramaglia, I., A. Jember, S. D. Pippig, A. D. Weinberg, N. Killeen, and M. Croft. 2000. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. Eur. J. Immunol. 165:3043.
56. Maxwell, J., A. D. Weinberg, R. A. Prell, and A. T. Vella. 2000. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J. Immunol. 164:107.
57. Hurtado, J. C., Y. J. Kim, and B. S. Kwon. 1997. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J. Immunol. 158:2600.
58. + T cell proliferation and lead to the amplification in vivo of cytotoxic immune responses. J. Exp. Med. 186:47.
59. Melero, I., W. W. Shuford, S. A. Newby, A. Aruffo, J. A. Ledbetter, K. E. Hellstrom, R. S. Mittler, and L. Chen. 1997. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3:682.
60. Tan, J. T., J. K. Whittmire, R. Ahmed, T. C. Pearson, and C. P. Larsen. 1999. 4-1BB ligand, a member of the TNF family, is important for the generation of anti-viral CD8 T cell responses. J. Immunol. 163:4859.
61. Takahashi, C., R. S. Mittler, and A. T. Vella. 1999. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol. 162:5037.
62. Wen, T., J. Bukczynski, and T. H. Watts. 2002. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J. Immunol. 168:4897.
63. Miller, D. G., M. A. Adam, and A. D. Miller. 1990. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10:4239.
64. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1991. Sequences of Proteins of Immunological Interest. National Institutes of Health, Bethesda.
65. Weissman, A. M., M. Baniyash, D. Hou, E. Samelson, W. H. Burgess, and R. D. Klausner. 1988. Molecular cloning of the ζ chain of the T cell antigen receptor. Science 239:1018.
66. Moingeon, P., C. C. Stebbins, L. D'Adamio, J. Lucich, and E. L. Reinherz. 1990. Human natural killer cells and mature T lymphocytes express identical CD3 ζ subunits as defined by cDNA cloning and sequence analysis. Eur. J. Immunol. 20:1741.
67. Aruffo, A., and B. Seed. 1987. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc. Natl. Acad. Sci. USA 84:8573.
68. Krause, D., C. Shearman, W. Lang, E. J. Kanzy, and R. Kurrle. 1990. Determination of affinities of murine and chimeric anti α/β-T-cell receptor antibodies by flow cytometry. Behring Inst. Mitt. 87:56.
69. Andrews, R. G., B. Torok-Storb, and I. D. Bernstein. 1983. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 62:124.
70. + T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood 100:933.
71. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8:379.
72. + T cell response. J. Immunol. 168:5455.
73. Isakov, N. 1998. ITAMs: immunoregulatory scaffolds that link immunoreceptors to their intracellular signaling pathways. Receptors Channels 5:243.
74. Pages, F., M. Ragueneau, R. Rottapel, A. Truneh, J. Nunes, J. Imbert, and D. Olive. 1994. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T cell signalling. Nature 369:327.
75. Prasad, K. V. S., Y.-C. Cai, M. Raab, B. Duckworth, L. Cantley, S. E. Shoelson, and C. E. Rudd. 1994. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc. Natl. Acad. Sci. USA 91:2834.
76. Coyle, A. J., S. Lehar, C. Lloyd, J. Tian, T. Delaney, S. Manning, T. Nguyen, T. Burwell, H. Schneider, J. A. Onzalo, et al. 2000. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 13:95.
77. Inoue, J., T. Ishida, N. Tsukamoto, N. Kobayashi, S. Azuma, and T. Yamamto. 2000. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signalling. Exp. Cell Res. 254:14.
78. Arch, R. H., and C. B. Thompson. 1998. 4-1BB and OX-40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor κB. Mol. Cell. Biol. 18:558.
79. Kawamata, S., T. Hori, A. Imura, A. Takori-Kondo, and T. Uchiyama. 1998. Activation of OX-40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NK-κB activation. J. Biol. Chem. 273:5808.
80. Jang, I. K., Z. H. Lee, Y. J. Kim, and B. S. Kwon. 1998. Human 4-1BB (CD137) signals sre mediated by TRAF2 and activate nuclear factor-κB. Biochem. Biophys. Res. Commun. 242:613.
81. Saoulli, K., S. Y. Lee, J. L. Cannons, W. C. Yeh, A. Snatana, M. D. Goldstein, N. Bangia, M. A. DeBedette, T. W. Mak, Y. Coi, and T. H. Watts. 1998. CD28-independent TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J. Exp. Med. 187:1849.